Drug intelligence / Profile preview

wheat dextrin + ethinyl estradiol + desogestrel

Development stage: Unknown
Lead developer: University of Pennsylvania
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This combination intervention is being evaluated in the CORS-PCOS Phase 2 clinical trial at the University of Pennsylvania. It consists of a standard low-dose oral contraceptive pill (containing 20 micrograms of ethinyl estradiol and 0.15 mg of desogestrel) supplemented with 15 grams per day of resistant starch derived from wheat dextrin. The study aims to treat Polycystic Ovary Syndrome (PCOS) and its associated metabolic syndrome in overweight or obese women. While oral contraceptives are a first-line treatment for managing the hormonal symptoms of PCOS, they can potentially exacerbate insulin resistance. The addition of wheat dextrin, a soluble prebiotic fiber, is intended to modulate the gut microbiota and promote the production of short-chain fatty acids (SCFAs) through colonic fermentation, thereby improving cardiometabolic parameters and addressing gut dysbiosis.

Other names: Resistant Starch in Polycystic Ovary Syndromewheat dextrin + oral contraceptives

Targets

PR (Progesterone receptor)ER (Estrogen receptor)

Beyond the preview

Go deeper on wheat dextrin + ethinyl estradiol + desogestrel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on wheat dextrin + ethinyl estradiol + desogestrel.

Explore the full profile